|Bid||20.52 x 0|
|Ask||20.54 x 0|
|Day's range||20.38 - 20.81|
|52-week range||19.18 - 26.94|
|Beta (5Y monthly)||0.10|
|PE ratio (TTM)||25.00|
|Earnings date||30 Jul 2021 - 09 Aug 2021|
|Forward dividend & yield||0.36 (1.61%)|
|Ex-dividend date||03 Jun 2021|
|1y target est||25.56|
(Bloomberg) -- Grifols SA agreed to buy Biotest AG for about 1.6 billion euros ($1.9 billion), pouncing after U.S. regulators pushed back on Chinese shareholder Creat Group Corp.’s expansion into the blood-plasma industry.Grifols offered 43 euros for each ordinary share and 37 euros for each preferred share, the Spanish company said Friday. That’s 23% and 4.2% higher than Thursday’s closing prices, respectively. Bloomberg News reported late Thursday that the deal was imminent.Creat’s strategy to
MADRID (Reuters) -Spanish pharmaceuticals company Grifols proposed a 1.6 billion euro ($1.9 billion) takeover of its German rival Biotest on Friday, in a move to consolidate the plasma-based drug industry. Grifols said it had agreed with Tiancheng International Investment to buy the Hong Kong-based company's controlling stake in Biotest for 1.1 billion euros. The Barcelona-based company agreed to buy 89.88% of Biotest's ordinary shares that carry voting rights, but which represent only 44.54% of the company's capital, and a further 0.54% of capital in preferred shares that do not carry voting rights, from Hong Kong-based Tiancheng.
Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.